Euro
USD
British Pound
NULL
Product Description
The research-grade biosimilar is a fully-humanized IgG1 monoclonal antibody that targets cytotoxic T-lymphocyte antigen 4 (CTLA-4). By binding to CTLA-4, it releases the inhibitory action on cytotoxic T-lymphocytes and thus destroys cancer cells. The original monoclonal antibody is approved by the FDA to treat metastatic melanoma, metastatic colorectal cancer, and hepatocellular carcinoma. The antibody is also recommended in combination therapy with Nivolumab for advanced renal cell carcinoma
Biovision | A2110 | Anti-CTLA-4 (Ipilimumab), Humanized Antibody DataSheet
Antibody Target: CTLA-4
Target Alternative Name: CD, GSE, GRD4, ALPS5, CD152, CTLA-4, IDDM12, CELIAC3, CTLA4
Tag Line: Fully-humanized IgG1 monoclonal antibody that binds with high affinity and inhibits cytotoxic T lymphocyte antigen-4 (CTLA-4). Inhibition of CTLA-4 activates T-lymphocyte and ultimately results in tumor cell death
Category: Primary antibody
Host: CHO cells
Isotype: Human IgG1
Species Reactivities:
Immunogen Sequence: Ipilimumab
Accession #: DB06186
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: Lot specific
Formulation: In PBS buffer, pH 7.2
Purification:
Application: In vivo studies,Cell proliferation assay
Positive Control:
Application And Usages: Cell proliferation assay, In vivo studies
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
